Skip to content

Arvinas ARVN Operating margin

Operating margin at other companies

Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-439.3%+35.3pp
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-697.7%+635pp
Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
-345.2%
Immunome logo
ImmunomeIMNM
-5,947.9%-12,002pp
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
-10,386.5%-5,025pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-168.6%-52.7pp

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Calculated from Arvinas’s reported figures.

Based on trailing twelve months.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's operating margin?
Arvinas (ARVN) reported operating margin of -283.8% in Q1 2026.
How has Arvinas's operating margin changed year-over-year?
Arvinas's operating margin decreased by 1167.2% year-over-year, from -22.4% to -283.8%.
What is the long-term trend for Arvinas's operating margin?
Over 4 years (2020 to 2025), Arvinas's operating margin has grown at a -44.2% compound annual growth rate (CAGR), from -466.4% to -45.1%.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.